Unknown NA INTERVENTIONAL 2-arm NCT01924624

Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma

Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma.: a Randomized Controlled Trial

Sponsor: The First Affiliated Hospital of Xiamen University

Conditions Hepatocellular Carcinoma Recurrence

Interventions Thalidomide

Updated 6 times since 2017 Last updated: Aug 15, 2013 Started: Jul 31, 2013 Primary completion: Aug 31, 2015 Completion: Dec 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Hepatocellular Carcinoma and Recurrence, this trial is ongoing. The trial is conducted by The First Affiliated Hospital of Xiamen University and has accumulated 6 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jan 2020 — Jan 2021 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jun 2018 — Jan 2020 [monthly]

Recruiting NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting NA

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The First Affiliated Hospital of Xiamen University

Data source: The First Affiliated Hospital of Xiamen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xiamen, China